Home
Contact Us

Fighting Alzheimer's disease!

 

VFP Therapies is a R&D-based young company in the pharmaceutical domain that design innovative drug candidates for the treatment of Alzheimer's disease.

Founded by Dr. Francis Marsais, VFP Therapies has developed an innovative vectorization-based ‘smart drugs' concept. Such drugs can be administered under a non-active form called bio-precursor.

 

 “I created VFP Therapies to find a solution to this major problem that is Alzheimer's disease. It is a global public health issue that cannot be underestimated.

Our business vision is to bring hope to mankind as conceptors of new treatments for the brain diseases and we are confident that our on-going R&D efforts will lead to a significant quantum jump in the treatment of Alzheimer's disease

 

Dr. Francis Marsais President and Founder of VFP Therapies

VFP Therapies is in the forefront


VFP Therapies
hold two families of patents via an exclusive and unlimited licensing agreement with INSA, Institut National des Sciences Appliquées, a major French academic engineer and research institute.

Its objective is the development of a proprietary line of products, starting with two families of compounds. The aim is to progress as far as possible on the path of clinical tests.

Alzheimer's Disease: a still incurable dementia

 

Dementia is a syndrome that can be caused by a number of progressive disorders that affect memory, thinking, behavior and the ability to perform everyday activities.

Alzheimer's disease is the most common type of dementia; it accounts for an estimated 60 to 80 percent of cases.
Alzheimer's disease was first described by German psychiatrist and neuropathologist Alois Alzheimer in 1906 and was named after him.

Over the last decade, scientists have substantially progressed in understanding potential environmental, genetic and other risk factors for Alzheimer's disease, the processes leading to formation of plaques and tangles in the brain, and the brain regions that are affected.

More effective treatment options are used but Alzheimer's disease is still incurable. The drugs currently in use treat only the symptoms, not the cause of the disorder, and they only slow the progression of cognitive decline.

 

Worldwide massive health and economic impact

In France 880,000 people suffer from Alzheimer type of dementia, 5.4 million in the USA and over 35 million in the world.

Surveys indicate that 65 million people will suffer from Alzheimer by 2030 and 115 million by 2050

  

The total estimated worldwide costs of dementia are $604 billion in 2010.

If dementia care were a country, it would be the world's 18th largest economy! 

2017 © VFP Therapies Hébergement & Support Le plus du Web - Création graphique Pratikmedia - Site géré et suivi par Studionet